{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T03:14:52Z","timestamp":1774322092851,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The inflammatory bowel disease, containing Crohn\u2019s disease and ulcerative colitis, was rare in the population, especially in the complication of kidney disease. A few studies had found proteinuria played a potential indicator\u00a0of inflammatory bowel disease occurrence and activity. This study aimed to better define the histopathologic spectrum and\u00a0study the outcome of renal disease in Crohn\u2019s disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective study of 3557 Crohn's disease from January 1<jats:sup>st<\/jats:sup>, 2016 to July 1<jats:sup>st<\/jats:sup>, 2021 in the Sixth Affiliated Hospital of Sun Yat-sen University identified 20 (0.56% [20\/3557]) patients who underwent kidney biopsy. All biopsy specimens were examined by standard procedures containing light microscopy, immunofluorescence, and electron microscopy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty cases were shown in this review study. Subnephrotic proteinuria (30% [6 of 20]), persistent hematuria and proteinuria (25% [5 of 20]), and isolated hematuria with acanthocytes (25% [5 of 20]) were the main indications for kidney biopsy. The most common diagnosis was IgA nephropathy (70% [14\/20]), followed by minimal change disease (10% [2\/20]), acute interstitial nephritis (5% [1\/20]), granulomatous interstitial nephritis (5% [1\/20]), non-IgA mesangial proliferative nephritis (5% [1\/20]) and thin basement membrane nephropathy (5% [1\/20]). The Lee classification of IgA nephropathy was mostly II or III level. Glomerular mesangial hyperplasia was the most common\u00a0pathologic manifestation according to the MEST-C Sore. After twelve-month treatment, the majority of patients turned to complete remission of renal disease by measuring proteinuria, while 3 patients still stayed in the relapse stage and 6 patients turned to partial remission by measuring hematuria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IgA nephropathy is the most common kidney biopsy diagnosis in Crohn's disease. Renal damage in Crohn's disease mainly involves the glomerulus, especially the mesangial matrix. After the treatment, proteinuria might be in remission, but hematuria remains.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-022-02883-8","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T22:30:41Z","timestamp":1658183441000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The pathological and outcome characteristics of renal lesions in Crohn\u2019s disease"],"prefix":"10.1186","volume":"23","author":[{"given":"Zhihui","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yejing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"issue":"1","key":"2883_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","volume":"13","author":"HS de Souza","year":"2016","unstructured":"de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13(1):13\u201327. https:\/\/doi.org\/10.1038\/nrgastro.2015.186.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2883_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fmed.2018.00183","volume":"5","author":"G Cui","year":"2018","unstructured":"Cui G, Yuan A. A Systematic Review of Epidemiology and Risk Factors Associated With Chinese Inflammatory Bowel Disease. Front Med (Lausanne). 2018;5:183. https:\/\/doi.org\/10.3389\/fmed.2018.00183.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"2883_CR3","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1572-0241.1998.156_b.x","volume":"93","author":"DS Pardi","year":"1998","unstructured":"Pardi DS, Tremaine WJ, Sandborn WJ, McCarthy JT. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol. 1998;93(4):504\u201314. https:\/\/doi.org\/10.1111\/j.1572-0241.1998.156_b.x.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2883_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.rdc.2018.06.007","volume":"44","author":"JM Ambruzs","year":"2018","unstructured":"Ambruzs JM, Larsen CP. Renal Manifestations of Inflammatory Bowel Disease. Rheum Dis Clin North Am. 2018;44(4):699\u2013714. https:\/\/doi.org\/10.1016\/j.rdc.2018.06.007.","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"2883_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2215\/CJN.04660513","volume":"9","author":"JM Ambruzs","year":"2014","unstructured":"Ambruzs JM, Walker PD, Larsen CP. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol. 2014;9(2):265\u201370. https:\/\/doi.org\/10.2215\/CJN.04660513.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2883_CR6","first-page":"381","volume":"81","author":"MMA Elaziz","year":"2018","unstructured":"Elaziz MMA, Fayed A. Patterns of renal involvement in a cohort of patients with inflammatory bowel disease in Egypt. Acta Gastroenterol Belg. 2018;81(3):381\u20135.","journal-title":"Acta Gastroenterol Belg"},{"issue":"5","key":"2883_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/ckj\/sfz004","volume":"12","author":"J Pohjonen","year":"2019","unstructured":"Pohjonen J, Nurmi R, Metso M, et al. Inflammatory bowel disease in patients undergoing renal biopsies. Clin Kidney J. 2019;12(5):645\u201351. https:\/\/doi.org\/10.1093\/ckj\/sfz004.","journal-title":"Clin Kidney J"},{"key":"2883_CR8","doi-asserted-by":"publisher","unstructured":"Park S, Lee HJ, Han KD, et al. Proteinuria Is Associated with the Development of Crohn's Disease: A Nationwide Population-Based Study. J Clin Med. 2021;10(4):799. https:\/\/doi.org\/10.3390\/jcm10040799.","DOI":"10.3390\/jcm10040799"},{"issue":"11","key":"2883_CR9","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1136\/gut.35.11.1599","volume":"35","author":"N Mahmud","year":"1994","unstructured":"Mahmud N, Stinson J, O\u2019Connell MA, et al. Microalbuminuria in inflammatory bowel disease. Gut. 1994;35(11):1599\u2013604. https:\/\/doi.org\/10.1136\/gut.35.11.1599.","journal-title":"Gut"},{"issue":"3","key":"2883_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1046\/j.1365-2036.2001.00940.x","volume":"15","author":"KR Herrlinger","year":"2001","unstructured":"Herrlinger KR, Noftz MK, Fellermann K, Schmidt K, Steinhoff J, Stange EF. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther. 2001;15(3):363\u20139. https:\/\/doi.org\/10.1046\/j.1365-2036.2001.00940.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2883_CR11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3748\/wjg.v12.i5.739","volume":"12","author":"AC Poulou","year":"2006","unstructured":"Poulou AC, Goumas KE, Dandakis DC, et al. Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid? World J Gastroenterol. 2006;12(5):739\u201346. https:\/\/doi.org\/10.3748\/wjg.v12.i5.739.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"2883_CR12","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/MCG.0000000000000660","volume":"50","author":"CN Bernstein","year":"2016","unstructured":"Bernstein CN, Eliakim A, Fedail S, et al. World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. J Clin Gastroenterol. 2016;50(10):803\u201318. https:\/\/doi.org\/10.1097\/MCG.0000000000000660.","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"2883_CR13","first-page":"439","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study Gastroenterology. 1976;70(3):439\u201344.","journal-title":"National Cooperative Crohn's Disease Study Gastroenterology"},{"issue":"1","key":"2883_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2017","unstructured":"Gomoll\u00f3n F, Dignass A, Annese V, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn\u2019s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3\u201325. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw168.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2883_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5858\/133.2.181","volume":"133","author":"PD Walker","year":"2009","unstructured":"Walker PD. The renal biopsy. Arch Pathol Lab Med. 2009;133(2):181\u20138. https:\/\/doi.org\/10.5858\/133.2.181.","journal-title":"Arch Pathol Lab Med"},{"key":"2883_CR16","doi-asserted-by":"publisher","unstructured":"Cattran DC, Feehally J, Cook HT, et al. Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis.\u00a0Kidney Int Suppl. 2012;2(2):139\u2013274. https:\/\/doi.org\/10.1038\/kisup.2012.9.","DOI":"10.1038\/kisup.2012.9"},{"key":"2883_CR17","unstructured":"Hubert D, Beaufils M, Meyrier A. Immunoglobulin A glomerular nephropathy associated with inflammatory colitis. Apropos of 2 cases, Presse Med.\u00a01984;13(17):1083\u20131085."},{"key":"2883_CR18","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","volume":"2","author":"KN Lai","year":"2016","unstructured":"Lai KN, Tang SC, Schena FP, et al. IgA nephropathy Nat Rev Dis Primers. 2016;2:16001. https:\/\/doi.org\/10.1038\/nrdp.2016.1.","journal-title":"IgA nephropathy Nat Rev Dis Primers"},{"issue":"3","key":"2883_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1053\/j.semdp.2020.03.001","volume":"37","author":"JR Hassler","year":"2020","unstructured":"Hassler JR. IgA nephropathy: A brief review. Semin Diagn Pathol. 2020;37(3):143\u20137. https:\/\/doi.org\/10.1053\/j.semdp.2020.03.001.","journal-title":"Semin Diagn Pathol"},{"issue":"25","key":"2883_CR20","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402\u201314. https:\/\/doi.org\/10.1056\/NEJMra1206793.","journal-title":"N Engl J Med"},{"issue":"4","key":"2883_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193274","volume":"13","author":"J Hemminger","year":"2018","unstructured":"Hemminger J, Arole V, Ayoub I, et al. Acute glomerulonephritis with large confluent IgA-dominant deposits associated with liver cirrhosis. PLoS ONE. 2018;13(4): e0193274. https:\/\/doi.org\/10.1371\/journal.pone.0193274.","journal-title":"PLoS ONE"},{"issue":"4","key":"2883_CR22","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.kint.2018.02.030","volume":"94","author":"MK Saha","year":"2018","unstructured":"Saha MK, Julian BA, Novak J, et al. Secondary IgA nephropathy. Kidney Int. 2018;94(4):674\u201381. https:\/\/doi.org\/10.1016\/j.kint.2018.02.030.","journal-title":"Kidney Int"},{"issue":"1","key":"2883_CR23","doi-asserted-by":"publisher","first-page":"c18","DOI":"10.1159\/000324180","volume":"119","author":"SH Nasr","year":"2011","unstructured":"Nasr SH, D\u2019Agati VD. IgA-dominant postinfectious glomerulonephritis: a new twist on an old disease. Nephron Clin Pract. 2011;119(1):c18-25. https:\/\/doi.org\/10.1159\/000324180.","journal-title":"Nephron Clin Pract"},{"issue":"5","key":"2883_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00384-004-0696-z","volume":"20","author":"MJ Forshaw","year":"2005","unstructured":"Forshaw MJ, Guirguis O, Hennigan TW. IgA nephropathy in association with Crohn\u2019s disease. Int J Colorectal Dis. 2005;20(5):463\u20135. https:\/\/doi.org\/10.1007\/s00384-004-0696-z.","journal-title":"Int J Colorectal Dis"},{"issue":"4","key":"2883_CR25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"JC Rodrigues","year":"2017","unstructured":"Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677\u201386. https:\/\/doi.org\/10.2215\/CJN.07420716.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10084","key":"2883_CR26","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(17)30550-0.","journal-title":"Lancet"},{"issue":"5","key":"2883_CR27","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1681\/ASN.2022020201","volume":"33","author":"CK Cheung","year":"2022","unstructured":"Cheung CK, Barratt J. Further Evidence for the Mucosal Origin of Pathogenic IgA in IgA Nephropathy. J Am Soc Nephrol. 2022;33(5):873\u20135. https:\/\/doi.org\/10.1681\/ASN.2022020201.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2883_CR28","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ng.3118","volume":"46","author":"K Kiryluk","year":"2014","unstructured":"Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187\u201396. https:\/\/doi.org\/10.1038\/ng.3118.","journal-title":"Nat Genet"},{"issue":"10","key":"2883_CR29","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.26355\/eurrev_202205_28857","volume":"26","author":"J Yuan","year":"2022","unstructured":"Yuan J, Wang Z, Wang YP. Identification of common key genes associated with Crohn\u2019s Disease and IgA nephropathy. Eur Rev Med Pharmacol Sci. 2022;26(10):3607\u201320. https:\/\/doi.org\/10.26355\/eurrev_202205_28857.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"2883_CR30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.semnephrol.2018.05.020","volume":"38","author":"R Coppo","year":"2018","unstructured":"Coppo R. The Gut-Renal Connection in IgA Nephropathy. Semin Nephrol. 2018;38(5):504\u201312. https:\/\/doi.org\/10.1016\/j.semnephrol.2018.05.020.","journal-title":"Semin Nephrol"},{"issue":"5","key":"2883_CR31","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00281-021-00871-y","volume":"43","author":"L Gesualdo","year":"2021","unstructured":"Gesualdo L, Di Leo V, Coppo R. The mucosal immune system and IgA nephropathy. Semin Immunopathol. 2021;43(5):657\u201368. https:\/\/doi.org\/10.1007\/s00281-021-00871-y.","journal-title":"Semin Immunopathol"},{"issue":"2","key":"2883_CR32","first-page":"72","volume":"33","author":"R Coppo","year":"1990","unstructured":"Coppo R, Roccatello D, Amore A, et al. Effects of a gluten-free diet in primary IgA nephropathy. Clin Nephrol. 1990;33(2):72\u201386.","journal-title":"Clin Nephrol"},{"issue":"1","key":"2883_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1053\/j.ackd.2019.09.002","volume":"27","author":"A Adiga","year":"2020","unstructured":"Adiga A, Goldfarb DS. The Association of Mesalamine With Kidney Disease. Adv Chronic Kidney Dis. 2020;27(1):72\u20136. https:\/\/doi.org\/10.1053\/j.ackd.2019.09.002.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"2883_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/2231-0770.94804","volume":"2","author":"BM Firwana","year":"2012","unstructured":"Firwana BM, Hasan R, Chalhoub W, et al. Nephrotic syndrome after treatment of Crohn\u2019s disease with mesalamine: Case report and literature review. Avicenna J Med. 2012;2(1):9\u201311. https:\/\/doi.org\/10.4103\/2231-0770.94804.","journal-title":"Avicenna J Med"},{"issue":"1","key":"2883_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","volume":"4","author":"A Dignass","year":"2010","unstructured":"Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn\u2019s disease: Current management. J Crohns Colitis. 2010;4(1):28\u201362. https:\/\/doi.org\/10.1016\/j.crohns.2009.12.002.","journal-title":"J Crohns Colitis"},{"issue":"6903","key":"2883_CR36","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/bmj.307.6903.540","volume":"307","author":"AJ Archimandritis","year":"1993","unstructured":"Archimandritis AJ, Weetch MS. Kidney granuloma in Crohn\u2019s disease. BMJ. 1993;307(6903):540\u20131. https:\/\/doi.org\/10.1136\/bmj.307.6903.540.","journal-title":"BMJ"},{"issue":"3","key":"2883_CR37","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/jgh.14849","volume":"35","author":"SW Hong","year":"2020","unstructured":"Hong SW, Yoon H, Shin CM, et al. Clinical significance of granulomas in Crohn\u2019s disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2020;35(3):364\u201373. https:\/\/doi.org\/10.1111\/jgh.14849.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"2883_CR38","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00467-012-2126-8","volume":"27","author":"R Hueppelshaeuser","year":"2012","unstructured":"Hueppelshaeuser R, von Unruh GE, Habbig S, et al. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn\u2019s disease. Pediatr Nephrol. 2012;27(7):1103\u20139. https:\/\/doi.org\/10.1007\/s00467-012-2126-8.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"2883_CR39","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s004670050355","volume":"11","author":"D McCallum","year":"1997","unstructured":"McCallum D, Smith L, Harley F, Yiu V. IgA nephropathy and thin basement membrane disease in association with Crohn disease. Pediatr Nephrol. 1997;11(5):637\u201340. https:\/\/doi.org\/10.1007\/s004670050355.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"2883_CR40","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1681\/ASN.2012020148","volume":"24","author":"J Savige","year":"2013","unstructured":"Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol. 2013;24(3):364\u201375. https:\/\/doi.org\/10.1681\/ASN.2012020148.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2883_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2019.11.008","volume":"76","author":"GZ Yu","year":"2020","unstructured":"Yu GZ, Guo L, Dong JF, et al. Persistent Hematuria and Kidney Disease Progression in IgA Nephropathy: A Cohort Study. Am J Kidney Dis. 2020;76(1):90\u20139. https:\/\/doi.org\/10.1053\/j.ajkd.2019.11.008.","journal-title":"Am J Kidney Dis"},{"issue":"42","key":"2883_CR42","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.3748\/wjg.v24.i42.4798","volume":"24","author":"S Park","year":"2018","unstructured":"Park S, Chun J, Han KD, et al. Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study. World J Gastroenterol. 2018;24(42):4798\u2013808. https:\/\/doi.org\/10.3748\/wjg.v24.i42.4798.","journal-title":"World J Gastroenterol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02883-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02883-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02883-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T22:30:49Z","timestamp":1658183449000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02883-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2883"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02883-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"assertion":[{"value":"28 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with the ethical principles of the Declaration of Helsinki and the Methods for the Ethical Review of Biomedical Research Involving Humans issued by the National Health and Family Planning Commission of China. All experimental protocols were approved by the Ethics committee of Sixth Affiliated Hospital of Sun Yat-sen University (ID: 2021ZSLYEC-421).Ethics committee of Sixth Affiliated Hospital of Sun Yat-sen University waived the need of informed consent since the study didn\u2019t involve personal privacy, any further invasive interventions, or commercial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}